Identification of osteopontin as a novel marker for early hepatocellular carcinoma

Sufen Shang, Amelie Plymoth, Shaokui Ge, Ziding Feng, Hugo R. Rosen, Suleeporn Sangrajrang, Pierre Hainaut, Jorge A. Marrero, Laura Beretta

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

The aim of this study was to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis. We performed proteomic profiling of plasma from patients with cirrhosis or HCC and validated selected candidate HCC biomarkers in two geographically distinct cohorts to include HCC of different etiologies. Mass spectrometry profiling of highly fractionated plasma from 18 cirrhosis and 17 HCC patients identified osteopontin (OPN) as significantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy controls in two independent cohorts. OPN plasma levels were significantly elevated in HCC patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN alone or in combination with AFP had significantly better area under the receiver operating characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC. OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study including 22 patients who developed HCC during follow-up, OPN was already elevated 1 year before diagnosis. Conclusion: OPN was more sensitive than AFP for the diagnosis of HCC in all studied HCC groups. In addition, OPN performance remained intact in samples collected 1 year before diagnosis.

Original languageEnglish (US)
Pages (from-to)483-490
Number of pages8
JournalHepatology
Volume55
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Osteopontin
Hepatocellular Carcinoma
alpha-Fetoproteins
Fibrosis
Chronic Hepatitis B
Chronic Hepatitis C
Biomarkers

ASJC Scopus subject areas

  • Hepatology

Cite this

Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H. R., Sangrajrang, S., ... Beretta, L. (2012). Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 55(2), 483-490. https://doi.org/10.1002/hep.24703

Identification of osteopontin as a novel marker for early hepatocellular carcinoma. / Shang, Sufen; Plymoth, Amelie; Ge, Shaokui; Feng, Ziding; Rosen, Hugo R.; Sangrajrang, Suleeporn; Hainaut, Pierre; Marrero, Jorge A.; Beretta, Laura.

In: Hepatology, Vol. 55, No. 2, 02.2012, p. 483-490.

Research output: Contribution to journalArticle

Shang, S, Plymoth, A, Ge, S, Feng, Z, Rosen, HR, Sangrajrang, S, Hainaut, P, Marrero, JA & Beretta, L 2012, 'Identification of osteopontin as a novel marker for early hepatocellular carcinoma', Hepatology, vol. 55, no. 2, pp. 483-490. https://doi.org/10.1002/hep.24703
Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012 Feb;55(2):483-490. https://doi.org/10.1002/hep.24703
Shang, Sufen ; Plymoth, Amelie ; Ge, Shaokui ; Feng, Ziding ; Rosen, Hugo R. ; Sangrajrang, Suleeporn ; Hainaut, Pierre ; Marrero, Jorge A. ; Beretta, Laura. / Identification of osteopontin as a novel marker for early hepatocellular carcinoma. In: Hepatology. 2012 ; Vol. 55, No. 2. pp. 483-490.
@article{a58e76d5374e46c9bc0392be91c9f444,
title = "Identification of osteopontin as a novel marker for early hepatocellular carcinoma",
abstract = "The aim of this study was to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis. We performed proteomic profiling of plasma from patients with cirrhosis or HCC and validated selected candidate HCC biomarkers in two geographically distinct cohorts to include HCC of different etiologies. Mass spectrometry profiling of highly fractionated plasma from 18 cirrhosis and 17 HCC patients identified osteopontin (OPN) as significantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy controls in two independent cohorts. OPN plasma levels were significantly elevated in HCC patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN alone or in combination with AFP had significantly better area under the receiver operating characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC. OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study including 22 patients who developed HCC during follow-up, OPN was already elevated 1 year before diagnosis. Conclusion: OPN was more sensitive than AFP for the diagnosis of HCC in all studied HCC groups. In addition, OPN performance remained intact in samples collected 1 year before diagnosis.",
author = "Sufen Shang and Amelie Plymoth and Shaokui Ge and Ziding Feng and Rosen, {Hugo R.} and Suleeporn Sangrajrang and Pierre Hainaut and Marrero, {Jorge A.} and Laura Beretta",
year = "2012",
month = "2",
doi = "10.1002/hep.24703",
language = "English (US)",
volume = "55",
pages = "483--490",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Identification of osteopontin as a novel marker for early hepatocellular carcinoma

AU - Shang, Sufen

AU - Plymoth, Amelie

AU - Ge, Shaokui

AU - Feng, Ziding

AU - Rosen, Hugo R.

AU - Sangrajrang, Suleeporn

AU - Hainaut, Pierre

AU - Marrero, Jorge A.

AU - Beretta, Laura

PY - 2012/2

Y1 - 2012/2

N2 - The aim of this study was to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis. We performed proteomic profiling of plasma from patients with cirrhosis or HCC and validated selected candidate HCC biomarkers in two geographically distinct cohorts to include HCC of different etiologies. Mass spectrometry profiling of highly fractionated plasma from 18 cirrhosis and 17 HCC patients identified osteopontin (OPN) as significantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy controls in two independent cohorts. OPN plasma levels were significantly elevated in HCC patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN alone or in combination with AFP had significantly better area under the receiver operating characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC. OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study including 22 patients who developed HCC during follow-up, OPN was already elevated 1 year before diagnosis. Conclusion: OPN was more sensitive than AFP for the diagnosis of HCC in all studied HCC groups. In addition, OPN performance remained intact in samples collected 1 year before diagnosis.

AB - The aim of this study was to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis. We performed proteomic profiling of plasma from patients with cirrhosis or HCC and validated selected candidate HCC biomarkers in two geographically distinct cohorts to include HCC of different etiologies. Mass spectrometry profiling of highly fractionated plasma from 18 cirrhosis and 17 HCC patients identified osteopontin (OPN) as significantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy controls in two independent cohorts. OPN plasma levels were significantly elevated in HCC patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN alone or in combination with AFP had significantly better area under the receiver operating characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC. OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study including 22 patients who developed HCC during follow-up, OPN was already elevated 1 year before diagnosis. Conclusion: OPN was more sensitive than AFP for the diagnosis of HCC in all studied HCC groups. In addition, OPN performance remained intact in samples collected 1 year before diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84856387903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856387903&partnerID=8YFLogxK

U2 - 10.1002/hep.24703

DO - 10.1002/hep.24703

M3 - Article

VL - 55

SP - 483

EP - 490

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -